Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Misses Revenue Estimates

Core Insights - Vanda Pharmaceuticals reported a quarterly loss of $0.46 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.34, marking a surprise of -35.29% [1] - The company generated revenues of $52.59 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 4.38% [2] - Vanda has surpassed consensus EPS estimates three times over the last four quarters, indicating some volatility in earnings expectations [2] Financial Performance - The loss per share of $0.46 compares unfavorably to a loss of $0.08 per share a year ago, highlighting a significant decline in performance [1] - Year-over-year revenue increased from $50.47 million to $52.59 million, showing growth despite missing estimates [2] - The current consensus EPS estimate for the upcoming quarter is -$0.32, with expected revenues of $59.5 million, while the estimate for the current fiscal year is -$1.49 on revenues of $227.5 million [7] Market Position - Vanda shares have underperformed the market, losing about 2.5% since the beginning of the year, compared to the S&P 500's gain of 8.2% [3] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the bottom 41% of over 250 Zacks industries, suggesting a challenging environment for companies in this sector [8] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6]